TPM3 and differentiated thyroid carcinoma: [61] reported compelling direct clinical evidence from a Phase I trial: a patient with TPM3‐NTRK1 rearranged differentiated thyroid cancer treated with the NTRK/ROS1 inhibitor taletrectinib (DS‐6051b) achieved a durable partial response lasting 27 months, solidifying the targetability of this fusion.